1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag

First patient included in Chordate Medical's pilot study PM009

Chordate Medical Holding AB (publ) ("Chordate") announced today that the first patient has been included in the company's open pilot study PM009. The study aims to evaluate the effectiveness of Ozilia in the preventive treatment of patients with chronic migraine who do not respond to treatment with CGRP inhibitors and other migraine medications.

“PM009 is an important study with significant potential upside for the company. Every level of positive results from the study could represent a great opportunity for the company, as the patient group in question has very few treatment options left”, says Anders Weilandt, Chordate CEO.

PM009 is being conducted at King's College in London with three to four referring clinics and Dr. Jan Hoffmann as the responsible principal investigator. The goal is to include 25–30 patients in the study.

“PM009 is a pilot study where we can learn more about how Ozilia can help people with chronic migraine who have no other options left. The patients participating in the study have already tried at least three other preventive medications before being treated with CGRP inhibitors, and when they also do not respond to CGRP, there are not many more possibilities. Hopefully, Ozilia can have a positive effect for some of them”, says Jan Hermansson, Chordate CSO.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
First patient included in Chordate Medical's pilot study PM009

Datum 2023-12-04, kl 15:40
Källa MFN
Bifogade filer
First patient included in Chordate Medical's pilot study PM009
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!